<DOC>
	<DOCNO>NCT01817725</DOCNO>
	<brief_summary>Background : The HBsAg clearance rate interferon-treated responder significantly high lamivudine-treated responder , imply immune control key HBsAg clearance . There good chance increase cure rate investigator enhance HBV-specific immune response HBsAg level already come low level . Hypothesis : HBsAg-based vaccine enhance HBsAg clearance chronic hepatitis B patient whose HBsAg already &lt; =2000 IU/ml . Patients method : This pilot study enroll 20 chronic hepatitis B patient HBsAg ≦2000 IU/ml , hepatic decompensation , HIV coinfection , clinical immunodeficiency . Engerix-B vaccine ( 20μg &lt; 20 year old 40 μg ≥ 20 year old ) give every 2 month one year . HBsAg quantification , anti-HBs , HBV DNA survey regularly dose treatment period every 3 month another year follow last dose . Viral cellular factor study discover determinant affect HBsAg clearance . Aims 1 . To elucidate whether HBsAg-based vaccine reactivate host immunity eliminate chronic HBV infection patient low titer HBsAg . 2 . To delineate dos response ( HBsAg clearance decline rate ) correlation design feasible schedule future clinical trial large group patient . 3 . To discover viral host factor use biomarkers personalized vaccine therapy .</brief_summary>
	<brief_title>Effect Hepatitis B Vaccine Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study</brief_title>
	<detailed_description>Vaccination schedule : Engerix-B ( 20μg/ml , GlaxoSmithKline Biologicals ) administer intramuscularly 0 , 2 , 4 , 6 , 8 , 10 , 12 month HBsAg clearance . The dosage 20μg &lt; = 20 year old 40μg &gt; 20 year old . HBsAg anti-HBs : qHBsAg check commercial kit ( Elecsys , Roche Diagnostics , Indianapolis , IN ) baseline , right every dose , every 3 month follow last dose one year . ALT , AST , Alpha-fetoprotein , bilirubin anti-HBs check simultaneously .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Naïve treat chronic hepatitis B patient positive HBsAg negative HBeAg ; 2 . Quantitative serum HBsAg ( qHBsAg ) &lt; 2000 IU/ml ; 3 . No HIV coinfection ; 4 . No obvious immunodeficiency ( renal failure , chemotherapy , radiotherapy , immunosuppressant ) ; 5 . Aged 3 80 year ; 1 . Pregnancy 2 . Allergic HBV vaccine yeast . 3 . Hepatic decompensation</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Therapeutic vaccine</keyword>
	<keyword>HBsAg clearance</keyword>
	<keyword>Immune clearance</keyword>
	<keyword>HBsAg clearance induce vaccination</keyword>
	<keyword>seroconversion carrier vaccination</keyword>
</DOC>